SEC Comment Letter 0000000000-23-013572 to Chemours Co (CC) (CIK 0001627223) (CC)
Chemours Co (CC) (CIK 0001627223)
Date: Dec. 13, 2023 · CIK: 0001627223 · Accession: 0000000000-23-013572
AI Filing Summary & Sentiment
File numbers found in text: 001-36794
Show Raw Text
United States securities and exchange commission logo
December 13, 2023
Jonathan Lock
Senior Vice President, Chief Financial Officer
Chemours Co
1007 Market Street
Wilmington, Delaware 19801
Re:Chemours Co
Form 10-K for Fiscal Year ended December 31, 2022
Form 10-Q for Fiscal Quarter Ended September 30, 2023
File No. 001-36794
Dear Jonathan Lock:
We have reviewed your filings and have the following comments.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Form 10-K for Fiscal Year ended December 31, 2022
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations
Non-GAAP Financial Measures, page 64
1.We note the introduction into your presentation of non-GAAP measures, which refers to
free cash flows (FCF) as a performance measure. We further note the reconciliation of
FCF is from cash provided by operating activities, a liquidity measure. As such, please
revise your disclosures provided in accordance with Items 10(e)(1)(i)(C) and
10(e)(1)(i)(D) of Regulation S-K to consistently characterize your presentation of FCF.
Refer to Question 102.07 of the Compliance and Disclosure Interpretations for Non-
GAAP Financial Measures for additional guidance. Address this comment and all other
non-GAAP measure comments in both your period and current reports, as applicable.
2.For each non-GAAP measure presented, please present the most directly comparable
financial measure or measures calculated and presented in accordance with US GAAP in
accordance with Item 10(e)(1)(i)(A) of Regulation S-K and Question 102.10(a) of the
Compliance and Disclosure Interpretations for Non-GAAP Financial Measures. In this
FirstName LastNameJonathan Lock
Comapany NameChemours Co
December 13, 2023 Page 2
FirstName LastNameJonathan Lock
Chemours Co
December 13, 2023
Page 2
regard, we note your presentation of adjusted EBITDA margin, return on invested capital,
and net leverage ratio without presenting the comparable margin, percentage or ratio
calculated using the most comparable US GAAP measures.
3.For your presentation of return on invested capital and net leverage ratio using non-GAAP
measures, please revise the titles to clearly distinguish these measures as being based on
non-GAAP measures rather than US GAAP measures. Refer to Item 10(e)(1)(ii)(E) of
Regulation S-K for guidance.
4.Please revise your reconciliation of Adjusted EBIT to begin with the most comparable US
GAAP measure rather than another non-GAAP measure. Refer to Item 10(e)(1)(i)(B) of
Regulation S-K and Question 102.10(b) of the Compliance and Disclosure Interpretations
for Non-GAAP Financial Measures for guidance.
Form 10-Q for Fiscal Quarter Ended September 30, 2023
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Non-GAAP Financial Measures, page 73
5.Please expand the footnote disclosures you provide for the adjustments to discuss all
material components and to quantify each component discussed. For example, footnote 5
for the litigation-related charges of $675 million for the nine-months ended September 30,
2023, refers to litigation settlements, PFOA drinking water treatment accruals, and related
legal fees with a reference to Note 17. However, Note 17 discloses that $592 million was
recognized within selling, general and administrative expenses during the nine-months
ended September 30, 2023, which leaves $83 million of the adjustment unexplained
and/or unquantified.
6.We note that you are now referring to environmental remediation expenses that are
adjusted as non-recurring. Please remove this characterization of this adjustment or
explain how you were able to conclude this characterization is appropriate given that this
is an adjustment made every period presented. Refer to Item 10(e)(1)(ii)(B) of Regulation
S-K and Question 102.03 of the Compliance and Disclosure Interpretations for Non-
GAAP Financial Measures for guidance.
7.We note that you have included $28M for the write-off of certain raw materials inventory
within the restructuring, asset-related and other charges adjustment for the nine-months
ended September 30, 2023. With reference to ASC 420-10-S99-3, please tell us your
consideration of the guidance in Question 100.01 the Compliance and Disclosure
Interpretations for Non-GAAP Financial Measures for this portion of the adjustment.
8.We note your presentation of adjusted free cash flows beginning in the September 30,
2023 Form 10-Q. Please tell us how you concluded that adjusting FCFs for PFAS
litigation settlements is consistent with the guidance in Item 10(e)(1)(ii)(A) of Regulation
S-K.
FirstName LastNameJonathan Lock
Comapany NameChemours Co
December 13, 2023 Page 3
FirstName LastName
Jonathan Lock
Chemours Co
December 13, 2023
Page 3
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Tracey Houser at 202-551-3736 or Terence O'Brien at 202-551-3355 if
you have questions regarding comments on the financial statements and related matters.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services